32431-93-9 Usage
Description
4-BROMO-2-CHLOROTHIOPHENE is a thiophene derivative characterized by the presence of a bromine atom at the 4th position and a chlorine atom at the 2nd position in the thiophene ring. It is an organic compound with potential applications in the pharmaceutical and chemical industries due to its unique chemical structure.
Uses
Used in Pharmaceutical Industry:
4-BROMO-2-CHLOROTHIOPHENE is used as a key intermediate in the synthesis of hypolipidemic agents, which are drugs that help lower lipid levels in the blood. These agents are essential for managing and treating conditions such as hyperlipidemia and atherosclerosis, which are associated with an increased risk of cardiovascular diseases.
4-BROMO-2-CHLOROTHIOPHENE's unique structure allows it to be a valuable building block in the development of new drugs targeting lipid metabolism, making it a promising candidate for further research and development in the pharmaceutical industry.
Check Digit Verification of cas no
The CAS Registry Mumber 32431-93-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,2,4,3 and 1 respectively; the second part has 2 digits, 9 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 32431-93:
(7*3)+(6*2)+(5*4)+(4*3)+(3*1)+(2*9)+(1*3)=89
89 % 10 = 9
So 32431-93-9 is a valid CAS Registry Number.
InChI:InChI=1/C4H2BrClS/c5-3-1-4(6)7-2-3/h1-2H
32431-93-9Relevant articles and documents
2-AMINO-N-(AMINO-OXO-ARYL-LAMBDA6-SULFANYLIDENE)ACETAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE
-
Page/Page column 101; 102; 214, (2021/06/26)
The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 2-amino-N-(amino-oxo-aryl-λ6- sulfanylidene)acetamide compounds (referred to herein as ANASIA compounds) that, inter alia, inhibit (e.g., selectively inhibit) bacterial aminoacyl-tRNA synthetase (aaRS) (e.g., bacterial leucyl-tRNA synthetase, LeuRS). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit (e.g., selectively inhibit) bacterial aminoacyl-tRNA synthetase; to treat disorders that are ameliorated by the inhibition (e.g., selective inhibition) of bacterial aminoacyl-tRNA synthetase; to treat bacterial infections; etc.
THIENYL COMPOUNDS
-
Page/Page column 16, (2008/06/13)
Compounds of formula I : and pharmaceutically-acceptable salts thereof, wherein Ar and R are as defined in the specification, compositions containing such compounds and the use of such compounds and compositions for use in therapy.
